Loss of SETD2 in wild‐type VHL clear cell renal cell carcinoma sensitizes cells to STF‐62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis

Mathieu Johnson,Sandra Turcotte
DOI: https://doi.org/10.1002/1878-0261.13770
2024-11-28
Molecular Oncology
Abstract:Vulnerability to the small molecule STF‐62247 is observed in SETD2‐inactivated VHL‐positive clear cell renal cell carcinoma (ccRCC) cells. DNA damage and loss of CDC25A leads to cell cycle arrest in S phase. Cleavage of caspase‐3 (CASP3) and gasdermin E (GSDME) suggests cell death by pyroptosis. Loss of chromosome 3p and loss of heterogeneity of the von Hippel–Lindau (VHL) gene are common characteristics of clear cell renal cell carcinoma (ccRCC). Despite frequent mutations on VHL, a fraction of tumors still grows with the expression of wild‐type (WT) VHL and evolve into an aggressive subtype. Additionally, mutations on chromatin‐modifying genes, such as the gene coding for the histone methyltransferase SET containing domain 2 (SETD2), are essential to ccRCC evolution. We previously identified STF‐62247, a small molecule first discovered as a synthetically lethal molecule for VHL‐deficient cells by blocking late stages of autophagy. This study investigated how other commonly mutated genes in ccRCC could impact the response to STF‐62247. We showed that SETD2 inactivation in ccRCC cells expressing WT‐VHL became vulnerable to STF‐62247, as indicated by decreases in cell proliferation and survival. Furthermore, activation of the DNA damage response pathway leads to the loss of M‐phase inducer phosphatase 1 (CDC25A) and cell cycle arrest in S phase. Cleavage of both caspase‐3 and gasdermin E suggests that STF‐62247 eliminates WT‐VHL ccRCC cells through pyroptosis specifically when SETD2 is inactivated.
oncology
What problem does this paper attempt to address?